Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07850973 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors

Name: Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell Tumors — clinical trial record (NCT07850973)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 1/2

SponsorM.D. Anderson Cancer Center

Started2027-03-01

View on ClinicalTrials.gov ↗

M.D. Anderson Cancer Center

1,223 trials monitored

See 78 trials at risk

The goal of this clinical research study is to find the highest safe dose of olaparib that can be combined with chemotherapy drugs and stem cell transplantation to treat patients with relapsed and refractory germ cell cancer. The safety and effectiveness of this treatment combination therapies will also be studied.

Trial Details

NCT Number	NCT07850973
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Germ Cell Cancer
Enrollment	36 participants
Start Date	2027-03-01
Primary Completion	2029-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-10-01